252 results on '"Neuzillet C"'
Search Results
2. Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey
3. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective
4. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
5. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
6. Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by the EORTC GI Tract Cancer Group
7. Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma
8. 139P Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
9. Cancers des voies biliaires : nouvelles approches thérapeutiques médicales orientées par les données moléculaires
10. LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study
11. Nutritional intervention with adapted physical activity (APA) in patients (PTS) with advanced pancreatic cancer (NUTAPACAP): An ancillary of the apacap gercor randomized controlled trial
12. Recommandations pour la pratique clinique Cancer du rectum: Question 5 Quelle est la place du traitement local ou de la simple surveillance après radiochimiotherapie neoadjuvante ?
13. Facteurs pronostiques de l’adénocarcinome pancréatique résécable
14. Prognostic factors for resectable pancreatic adenocarcinoma
15. Brèves de l’AERIO
16. 75P Tumor mutational burden in clinical routine practice: Identifying the right threshold?
17. 1487TiP A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY)
18. PO-1263 Exclusive radiotherapy in early stage anal cancer - outcomes, patterns and predictors of relapse
19. Intérêt de la chirurgie pour le traitement des adénopathies rétro-péritonéales d’un cancer colorectal. Étude rétrospective monocentrique
20. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer
21. 595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
22. 1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
23. 1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
24. 557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
25. 120P Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
26. 121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
27. Biomarqueurs prédictifs d’efficacité
28. Épidémiologie et parcours de soins des cholangiocarcinomes intrahépatiques (iCCA) en France : données de vie réelle issues du Programme de médicalisation des systèmes d’information
29. 1566TiP PRODIGE 65 - UCGI 36 - GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma
30. 60P Epidemiology and patterns of care of intrahepatic cholangiocarcinoma (iCCA) in France: Real life data from the French National Hospital-Discharge Summaries database system (PMSI)
31. 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial
32. 435P Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study
33. Management of pancreatic ductal adenocarcinoma (PDAC): Progress in the past decade and challenges for the future
34. Impact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey
35. A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)
36. Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations
37. Feasibility and barriers to optimal oncological treatment in solid organ transplant patients with de novo cancer
38. P-139Efficacy of a Sequential Treatment Strategy with GEMOX Followed by FOLFIRI in Advanced Cholangiocarcinoma
39. 830TiP - A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)
40. 555P - Impact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey
41. Targeting cancer cell metabolism in pancreatic adenocarcinoma
42. Second line therapy with sunitinib as single agent in patients with advanced intrahepatic cholangiocarcinoma (update on SUN-CK phase II trial)
43. 765P - Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations
44. Recommandations pour la pratique clinique Cancer du rectum
45. 2352 Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma: Final results of the SUN-CK phase II trial from GERCOR IRC
46. P-139 Efficacy of a Sequential Treatment Strategy with GEMOX Followed by FOLFIRI in Advanced Cholangiocarcinoma
47. 1466P - Feasibility and barriers to optimal oncological treatment in solid organ transplant patients with de novo cancer
48. Second Line Therapy with Sunitinib As Single Agent in Patients with Advanced Intrahepatic Cholangiocarcinoma (Update on Sun-Ck Phase Ii Trial)
49. Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience
50. AERIO News in Brief
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.